Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Analysts at Jones Trading

Equities research analysts at Jones Trading initiated coverage on shares of Palvella Therapeutics (NASDAQ:PVLA) in a research note issued to investors on Tuesday,Benzinga reports. The firm set a “buy” rating and a $45.00 price target on the stock. Jones Trading’s price objective would indicate a potential upside of 61.46% from the company’s current price.

Several other research firms have also issued reports on PVLA. HC Wainwright reiterated a “buy” rating and issued a $38.00 target price on shares of Palvella Therapeutics in a research note on Tuesday, February 11th. Scotiabank assumed coverage on shares of Palvella Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 price objective for the company. TD Cowen started coverage on shares of Palvella Therapeutics in a research report on Wednesday, February 5th. They set a “buy” rating and a $44.00 target price on the stock. Cantor Fitzgerald assumed coverage on Palvella Therapeutics in a report on Wednesday, December 18th. They issued an “overweight” rating for the company. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $39.00 price target on shares of Palvella Therapeutics in a research report on Wednesday, February 26th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $43.20.

Palvella Therapeutics Stock Performance

Shares of NASDAQ:PVLA opened at $27.87 on Tuesday. The firm’s 50 day moving average is $19.08. Palvella Therapeutics has a 12-month low of $6.20 and a 12-month high of $29.27. The stock has a market capitalization of $312.73 million, a PE ratio of -2.30 and a beta of 0.54.

Institutional Investors Weigh In On Palvella Therapeutics

Several large investors have recently modified their holdings of PVLA. BML Capital Management LLC purchased a new position in Palvella Therapeutics in the fourth quarter valued at approximately $506,000. Frazier Life Sciences Management L.P. purchased a new stake in Palvella Therapeutics in the 4th quarter worth about $7,847,000. Cresset Asset Management LLC bought a new stake in Palvella Therapeutics in the 4th quarter valued at about $251,000. Suvretta Capital Management LLC bought a new position in Palvella Therapeutics during the fourth quarter worth about $8,574,000. Finally, DAFNA Capital Management LLC purchased a new position in shares of Palvella Therapeutics in the fourth quarter worth about $857,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.